MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Clinical trials for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) explained in plain language.
Never miss a new study
Get alerted when new MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) trials appear
Sign up with your email to follow new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough prostate cancer: drug combo aims to delay progression
Disease control Recruiting nowThis study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat prostate cancer: Drug-Radiation combo trial launches
Disease control Recruiting nowThis study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus r…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug duo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the comb…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for advanced cancer: MHB048C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB048C in 200 adults with advanced solid tumors (like prostate cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV, and researchers m…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill takes on Hard-to-Treat prostate cancer in early human trial
Disease control Recruiting nowThis early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New imaging study aims to unmask why some prostate cancer metastases resist treatment
Knowledge-focused Recruiting nowThis study will use special PET scans with two different tracers to see how each individual prostate cancer metastasis responds to therapy. Researchers want to understand why some metastases shrink while others grow during the same treatment. The goal is to better characterize re…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: NA • Sponsor: Frederic Pouliot • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC